Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders :: workshop summary /
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Körperschaft: | |
| Format: | Elektronisch Tagungsbericht E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C. :
National Academies Press,
2015.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop. |
| Beschreibung: | Title from PDF title page. |
| Beschreibung: | 1 online resource (1 PDF file (xiv, 114 pages)) : illustrations |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9780309373241 0309373247 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn927362841 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d f | ||
| 007 | cr un||||||||| | ||
| 008 | 151202s2015 dcua obt 100 0 eng | ||
| 040 | |a NLM |b eng |e rda |e pn |c NLM |d CUS |d MMU |d N$T |d YDXCP |d EBLCP |d UAB |d BUF |d OCLCF |d OCLCO |d OCLCQ |d EZ9 |d OCLCA |d OCLCQ |d OCLCO |d WYU |d NLM |d OCLCO |d OCLCA |d OCLCQ |d OCLCO |d VLY |d VT2 |d UKAHL |d K6U |d OCLCO |d OCLCQ |d OCLCO | ||
| 016 | 7 | |a 101673538 |2 DNLM | |
| 019 | |a 1021278119 |a 1162309472 | ||
| 020 | |a 9780309373241 | ||
| 020 | |a 0309373247 | ||
| 020 | |z 9780309373234 |q (paperback) | ||
| 020 | |z 0309373239 |q (paperback) | ||
| 035 | |a (OCoLC)927362841 |z (OCoLC)1021278119 |z (OCoLC)1162309472 | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RM301.25 |b .N67 2015 | |
| 060 | 0 | 0 | |a 2016 C-538 |
| 060 | 1 | 0 | |a QV 76.5 |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.19 |2 23 | |
| 049 | |a MAIN | ||
| 111 | 2 | |a Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) |d (2015 : |c Washington, D.C.), |j author. |0 http://id.loc.gov/authorities/names/no2015147304 | |
| 245 | 1 | 0 | |a Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : |b workshop summary / |c Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| 264 | 1 | |a Washington, D.C. : |b National Academies Press, |c 2015. | |
| 300 | |a 1 online resource (1 PDF file (xiv, 114 pages)) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF title page. | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop. | |
| 536 | |a This project was supported by contracts between the National Academy of Sciences and AbbVie; the Alzheimer's Association; American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Brain Canada Foundation; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; the Department of Health and Human Services' Food and Drug Administration (Contract No. 1R13FD005154-01) and National Institutes of Health (NIH, Contract Nos. HHSN26300026 and HHSN263201200074I, Task Order HHSN26300023 [Under Master Base #DHHS-10001292]) through the National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Disease, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly and Company; FasterCures; Foundation for the National Institutes of Health; Friends of Cancer Research; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc. (Contract No. 005319); Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck & Co., Inc. (Contract No. CMO-141224-000649); The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. BCS-1064270); New England Journal of Medicine; One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited (Contract No. 53108); and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project. | ||
| 588 | 0 | |a Version viewed December 21, 2015. | |
| 505 | 0 | |a Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement. | |
| 546 | |a English. | ||
| 650 | 0 | |a Drug development |x Economic aspects |v Congresses. | |
| 650 | 0 | |a Central nervous system |x Diseases |x Effect of drugs on |v Congresses. | |
| 650 | 0 | |a Pharmaceutical industry |x Economic aspects |v Congresses. | |
| 650 | 0 | |a Public-private sector cooperation |v Congresses. | |
| 650 | 1 | 2 | |a Central Nervous System Agents |x economics |0 https://id.nlm.nih.gov/mesh/D002491Q000191 |
| 650 | 2 | 2 | |a Drug Discovery |x economics |0 https://id.nlm.nih.gov/mesh/D055808Q000191 |
| 650 | 2 | 2 | |a Financial Support |0 https://id.nlm.nih.gov/mesh/D005378 |
| 650 | 2 | 2 | |a Nervous System Diseases |x drug therapy |0 https://id.nlm.nih.gov/mesh/D009422Q000188 |
| 650 | 2 | 2 | |a Nervous System Diseases |x economics |0 https://id.nlm.nih.gov/mesh/D009422Q000191 |
| 650 | 2 | 2 | |a Private Sector |x economics |0 https://id.nlm.nih.gov/mesh/D017149Q000191 |
| 650 | 6 | |a Médicaments |x Développement |x Aspect économique |v Congrès. | |
| 650 | 6 | |a Système nerveux central |x Maladies |x Effets des médicaments sur |v Congrès. | |
| 650 | 6 | |a Industrie pharmaceutique |x Aspect économique |v Congrès. | |
| 650 | 6 | |a Partenariat public-privé |v Congrès. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry |x Economic aspects |2 fast | |
| 650 | 7 | |a Public-private sector cooperation |2 fast | |
| 655 | 2 | |a Congress |0 https://id.nlm.nih.gov/mesh/D016423 | |
| 655 | 7 | |a proceedings (reports) |2 aat | |
| 655 | 7 | |a Conference papers and proceedings |2 fast | |
| 655 | 7 | |a Conference papers and proceedings. |2 lcgft |0 http://id.loc.gov/authorities/genreForms/gf2014026068 | |
| 655 | 7 | |a Actes de congrès. |2 rvmgf | |
| 700 | 1 | |a Norris, Sheena M. Posey, |e author. | |
| 700 | 1 | |a Strauss, Evelyn, |e author. | |
| 700 | 1 | |a De Feo, Christopher Joseph, |e author. | |
| 700 | 1 | |a Stroud, Clare, |e author. | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Forum on Neuroscience and Nervous System Disorders, |e sponsoring body. |0 http://id.loc.gov/authorities/names/no2008032406 | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Forum on Drug Discovery, Development, and Translation, |e sponsoring body. |0 http://id.loc.gov/authorities/names/no2007051854 | |
| 776 | 0 | 8 | |i Print version: |t Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders. |d Washington, D.C. : National Academies Press, [2015] |z 0309373239 |w (OCoLC)921241584 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36564449 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36618103 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL4393789 | ||
| 938 | |a EBSCOhost |b EBSC |n 1029476 | ||
| 938 | |a YBP Library Services |b YANK |n 12724313 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn927362841 |
|---|---|
| _version_ | 1816882328534777856 |
| adam_text | |
| any_adam_object | |
| author | Norris, Sheena M. Posey Strauss, Evelyn De Feo, Christopher Joseph Stroud, Clare |
| author_corporate | Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) Washington, D.C.) |
| author_corporate_role | |
| author_facet | Norris, Sheena M. Posey Strauss, Evelyn De Feo, Christopher Joseph Stroud, Clare Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) Washington, D.C.) |
| author_role | aut aut aut aut |
| author_sort | Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) Washington, D.C.) |
| author_variant | s m p n smp smpn e s es f c j d fcj fcjd c s cs |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM301 |
| callnumber-raw | RM301.25 .N67 2015 |
| callnumber-search | RM301.25 .N67 2015 |
| callnumber-sort | RM 3301.25 N67 42015 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement. |
| ctrlnum | (OCoLC)927362841 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic Conference Proceeding eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>08037cam a2200889 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn927362841</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d f </controlfield><controlfield tag="007">cr un|||||||||</controlfield><controlfield tag="008">151202s2015 dcua obt 100 0 eng </controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NLM</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">NLM</subfield><subfield code="d">CUS</subfield><subfield code="d">MMU</subfield><subfield code="d">N$T</subfield><subfield code="d">YDXCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">UAB</subfield><subfield code="d">BUF</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">EZ9</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">WYU</subfield><subfield code="d">NLM</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VLY</subfield><subfield code="d">VT2</subfield><subfield code="d">UKAHL</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101673538</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1021278119</subfield><subfield code="a">1162309472</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309373241</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309373247</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780309373234</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0309373239</subfield><subfield code="q">(paperback)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)927362841</subfield><subfield code="z">(OCoLC)1021278119</subfield><subfield code="z">(OCoLC)1162309472</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">pcc</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM301.25</subfield><subfield code="b">.N67 2015</subfield></datafield><datafield tag="060" ind1="0" ind2="0"><subfield code="a">2016 C-538</subfield></datafield><datafield tag="060" ind1="1" ind2="0"><subfield code="a">QV 76.5</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="111" ind1="2" ind2=" "><subfield code="a">Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop)</subfield><subfield code="d">(2015 :</subfield><subfield code="c">Washington, D.C.),</subfield><subfield code="j">author.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2015147304</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders :</subfield><subfield code="b">workshop summary /</subfield><subfield code="c">Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C. :</subfield><subfield code="b">National Academies Press,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (1 PDF file (xiv, 114 pages)) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from PDF title page.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.</subfield></datafield><datafield tag="536" ind1=" " ind2=" "><subfield code="a">This project was supported by contracts between the National Academy of Sciences and AbbVie; the Alzheimer's Association; American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Brain Canada Foundation; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; the Department of Health and Human Services' Food and Drug Administration (Contract No. 1R13FD005154-01) and National Institutes of Health (NIH, Contract Nos. HHSN26300026 and HHSN263201200074I, Task Order HHSN26300023 [Under Master Base #DHHS-10001292]) through the National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Disease, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly and Company; FasterCures; Foundation for the National Institutes of Health; Friends of Cancer Research; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc. (Contract No. 005319); Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck & Co., Inc. (Contract No. CMO-141224-000649); The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. BCS-1064270); New England Journal of Medicine; One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited (Contract No. 53108); and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Version viewed December 21, 2015.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development</subfield><subfield code="x">Economic aspects</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Central nervous system</subfield><subfield code="x">Diseases</subfield><subfield code="x">Effect of drugs on</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Economic aspects</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Public-private sector cooperation</subfield><subfield code="v">Congresses.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Central Nervous System Agents</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D002491Q000191</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Drug Discovery</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D055808Q000191</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Financial Support</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D005378</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Nervous System Diseases</subfield><subfield code="x">drug therapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009422Q000188</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Nervous System Diseases</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D009422Q000191</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Private Sector</subfield><subfield code="x">economics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D017149Q000191</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement</subfield><subfield code="x">Aspect économique</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Système nerveux central</subfield><subfield code="x">Maladies</subfield><subfield code="x">Effets des médicaments sur</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Industrie pharmaceutique</subfield><subfield code="x">Aspect économique</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Partenariat public-privé</subfield><subfield code="v">Congrès.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Economic aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public-private sector cooperation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Congress</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D016423</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">proceedings (reports)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Conference papers and proceedings</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Conference papers and proceedings.</subfield><subfield code="2">lcgft</subfield><subfield code="0">http://id.loc.gov/authorities/genreForms/gf2014026068</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Actes de congrès.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Norris, Sheena M. Posey,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strauss, Evelyn,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Feo, Christopher Joseph,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stroud, Clare,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="b">Forum on Neuroscience and Nervous System Disorders,</subfield><subfield code="e">sponsoring body.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2008032406</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.).</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation,</subfield><subfield code="e">sponsoring body.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2007051854</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders.</subfield><subfield code="d">Washington, D.C. : National Academies Press, [2015]</subfield><subfield code="z">0309373239</subfield><subfield code="w">(OCoLC)921241584</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH36564449</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH36618103</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL4393789</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1029476</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12724313</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Congress https://id.nlm.nih.gov/mesh/D016423 proceedings (reports) aat Conference papers and proceedings fast Conference papers and proceedings. lcgft http://id.loc.gov/authorities/genreForms/gf2014026068 Actes de congrès. rvmgf |
| genre_facet | Congress proceedings (reports) Conference papers and proceedings Conference papers and proceedings. Actes de congrès. |
| id | ZDB-4-EBA-ocn927362841 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:26:52Z |
| institution | BVB |
| institution_GND | http://id.loc.gov/authorities/names/no2015147304 http://id.loc.gov/authorities/names/no2008032406 http://id.loc.gov/authorities/names/no2007051854 |
| isbn | 9780309373241 0309373247 |
| language | English |
| oclc_num | 927362841 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (1 PDF file (xiv, 114 pages)) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | National Academies Press, |
| record_format | marc |
| spelling | Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders (Workshop) (2015 : Washington, D.C.), author. http://id.loc.gov/authorities/names/no2015147304 Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. Washington, D.C. : National Academies Press, 2015. 1 online resource (1 PDF file (xiv, 114 pages)) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Title from PDF title page. Includes bibliographical references. The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop. This project was supported by contracts between the National Academy of Sciences and AbbVie; the Alzheimer's Association; American Diabetes Association; American Society of Microbiology; Amgen Inc. (Contract No. GHCCOPS-CSARF-63987); Association of American Medical Colleges; AstraZeneca; Baxter BioScience; Brain Canada Foundation; Burroughs Wellcome Fund (Contract No. 1015149); Critical Path Institute; the Department of Health and Human Services' Food and Drug Administration (Contract No. 1R13FD005154-01) and National Institutes of Health (NIH, Contract Nos. HHSN26300026 and HHSN263201200074I, Task Order HHSN26300023 [Under Master Base #DHHS-10001292]) through the National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Disease, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, and NIH Blueprint for Neuroscience Research; Department of Veterans Affairs (VA240-14-C-0057); Doris Duke Charitable Foundation (Contract No. 2015103); Eli Lilly and Company; FasterCures; Foundation for the National Institutes of Health; Friends of Cancer Research; the Gatsby Charitable Foundation; GlaxoSmithKline, Inc. (Contract No. 005319); Johnson & Johnson Pharmaceutical Research and Development, LLC; Lundbeck Research USA; Merck & Co., Inc. (Contract No. CMO-141224-000649); The Michael J. Fox Foundation for Parkinson's Research; the National Multiple Sclerosis Society; the National Science Foundation (Contract No. BCS-1064270); New England Journal of Medicine; One Mind for Research; Orion Bionetworks; Pfizer Inc.; Pharmaceutical Product Development, LLC; Sanofi; the Society for Neuroscience; Takeda Pharmaceutical Company Limited (Contract No. 53108); and Wellcome Trust. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for this project. Version viewed December 21, 2015. Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement. English. Drug development Economic aspects Congresses. Central nervous system Diseases Effect of drugs on Congresses. Pharmaceutical industry Economic aspects Congresses. Public-private sector cooperation Congresses. Central Nervous System Agents economics https://id.nlm.nih.gov/mesh/D002491Q000191 Drug Discovery economics https://id.nlm.nih.gov/mesh/D055808Q000191 Financial Support https://id.nlm.nih.gov/mesh/D005378 Nervous System Diseases drug therapy https://id.nlm.nih.gov/mesh/D009422Q000188 Nervous System Diseases economics https://id.nlm.nih.gov/mesh/D009422Q000191 Private Sector economics https://id.nlm.nih.gov/mesh/D017149Q000191 Médicaments Développement Aspect économique Congrès. Système nerveux central Maladies Effets des médicaments sur Congrès. Industrie pharmaceutique Aspect économique Congrès. Partenariat public-privé Congrès. MEDICAL Pharmacology. bisacsh Pharmaceutical industry Economic aspects fast Public-private sector cooperation fast Congress https://id.nlm.nih.gov/mesh/D016423 proceedings (reports) aat Conference papers and proceedings fast Conference papers and proceedings. lcgft http://id.loc.gov/authorities/genreForms/gf2014026068 Actes de congrès. rvmgf Norris, Sheena M. Posey, author. Strauss, Evelyn, author. De Feo, Christopher Joseph, author. Stroud, Clare, author. Institute of Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders, sponsoring body. http://id.loc.gov/authorities/names/no2008032406 Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation, sponsoring body. http://id.loc.gov/authorities/names/no2007051854 Print version: Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders. Washington, D.C. : National Academies Press, [2015] 0309373239 (OCoLC)921241584 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476 Volltext |
| spellingShingle | Norris, Sheena M. Posey Strauss, Evelyn De Feo, Christopher Joseph Stroud, Clare Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Introduction and overview -- Improving market protection -- Strengthening the regulatory pathway -- Patient benefit and engagement. Drug development Economic aspects Congresses. Central nervous system Diseases Effect of drugs on Congresses. Pharmaceutical industry Economic aspects Congresses. Public-private sector cooperation Congresses. Central Nervous System Agents economics https://id.nlm.nih.gov/mesh/D002491Q000191 Drug Discovery economics https://id.nlm.nih.gov/mesh/D055808Q000191 Financial Support https://id.nlm.nih.gov/mesh/D005378 Nervous System Diseases drug therapy https://id.nlm.nih.gov/mesh/D009422Q000188 Nervous System Diseases economics https://id.nlm.nih.gov/mesh/D009422Q000191 Private Sector economics https://id.nlm.nih.gov/mesh/D017149Q000191 Médicaments Développement Aspect économique Congrès. Système nerveux central Maladies Effets des médicaments sur Congrès. Industrie pharmaceutique Aspect économique Congrès. Partenariat public-privé Congrès. MEDICAL Pharmacology. bisacsh Pharmaceutical industry Economic aspects fast Public-private sector cooperation fast |
| subject_GND | https://id.nlm.nih.gov/mesh/D002491Q000191 https://id.nlm.nih.gov/mesh/D055808Q000191 https://id.nlm.nih.gov/mesh/D005378 https://id.nlm.nih.gov/mesh/D009422Q000188 https://id.nlm.nih.gov/mesh/D009422Q000191 https://id.nlm.nih.gov/mesh/D017149Q000191 https://id.nlm.nih.gov/mesh/D016423 http://id.loc.gov/authorities/genreForms/gf2014026068 |
| title | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / |
| title_auth | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / |
| title_exact_search | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / |
| title_full | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| title_fullStr | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| title_full_unstemmed | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : workshop summary / Sheena M. Posey Norris, Evelyn Strauss, Christopher DeFeo, and Clare Stroud, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies. |
| title_short | Financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders : |
| title_sort | financial incentives to encourage development of therapies that address unmet medical needs for nervous system disorders workshop summary |
| title_sub | workshop summary / |
| topic | Drug development Economic aspects Congresses. Central nervous system Diseases Effect of drugs on Congresses. Pharmaceutical industry Economic aspects Congresses. Public-private sector cooperation Congresses. Central Nervous System Agents economics https://id.nlm.nih.gov/mesh/D002491Q000191 Drug Discovery economics https://id.nlm.nih.gov/mesh/D055808Q000191 Financial Support https://id.nlm.nih.gov/mesh/D005378 Nervous System Diseases drug therapy https://id.nlm.nih.gov/mesh/D009422Q000188 Nervous System Diseases economics https://id.nlm.nih.gov/mesh/D009422Q000191 Private Sector economics https://id.nlm.nih.gov/mesh/D017149Q000191 Médicaments Développement Aspect économique Congrès. Système nerveux central Maladies Effets des médicaments sur Congrès. Industrie pharmaceutique Aspect économique Congrès. Partenariat public-privé Congrès. MEDICAL Pharmacology. bisacsh Pharmaceutical industry Economic aspects fast Public-private sector cooperation fast |
| topic_facet | Drug development Economic aspects Congresses. Central nervous system Diseases Effect of drugs on Congresses. Pharmaceutical industry Economic aspects Congresses. Public-private sector cooperation Congresses. Central Nervous System Agents economics Drug Discovery economics Financial Support Nervous System Diseases drug therapy Nervous System Diseases economics Private Sector economics Médicaments Développement Aspect économique Congrès. Système nerveux central Maladies Effets des médicaments sur Congrès. Industrie pharmaceutique Aspect économique Congrès. Partenariat public-privé Congrès. MEDICAL Pharmacology. Pharmaceutical industry Economic aspects Public-private sector cooperation Congress proceedings (reports) Conference papers and proceedings Conference papers and proceedings. Actes de congrès. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1029476 |
| work_keys_str_mv | AT financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopwashingtondc financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT norrissheenamposey financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT straussevelyn financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT defeochristopherjoseph financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT stroudclare financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT instituteofmedicineusforumonneuroscienceandnervoussystemdisorders financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation financialincentivestoencouragedevelopmentoftherapiesthataddressunmetmedicalneedsfornervoussystemdisordersworkshopsummary |